We work on some of the most complex molecules in development. Our scientists write about it, present on it, and share what they have learned, so you can move your program forward with more confidence. Drug product, nanomedicine, bioanalysis, drug substance. Written by the people who deliver these programs every day.
Live conferences and on-demand webinars where you can connect with our scientific team.
RESERVE YOUR SLOT Book a meeting at BioJapan 2026. Tell us what you are working on and we will line up the right person from our team to meet you at booth C-35. Book a 15–30 minute conversation 7–9 October with the specialist best suited to your topic. No obligation.
RESERVE YOUR SLOT Book a meeting at NLS Days 2026. Tell us what you are working on and we will line up the right person from our team to meet you at booth K:18. Book a 15–30 minute conversation 8–9 September with the specialist best suited to your topic. No obligation.
Hibreniguss (Hibre) Terefe, PhDDirector of Product Development & Site Head of R&D, Ardena Somerset SPEAKER SPOTLIGHT A CDMO Framework for Selecting and Scaling Solubility Enhancement Technologies Drawing on real-world development experience, Hibre will explore how factors such as API properties, dose, development stage and manufacturability can guide technology selection – helping teams de-risk scale-up, avoid […]
Insights and perspectives from our team on industry trends and scientific advances.
LNP manufacturing has become one of the fastest-growing areas in modern pharmaceutical development. Lipid nanoparticles (LNPs) have moved from a niche formulation approach to one of the most validated platforms for delivering complex therapeutic payloads, and demand for specialised development and manufacturing partners has grown alongside them. According to market research firm InsightAce Analytic, the […]
HPAPI contract manufacturing companies are not interchangeable, and choosing the right one is among the highest-stakes decisions in a potent-compound programme. Pick the wrong partner and it surfaces later: as a containment finding, a failed cleaning validation, or a technology transfer that stalls before your first batch. This guide is about how to make that […]
In the fast-paced world of early-phase drug development, successful formulation development is often the bridge between a promising molecule and a viable clinical candidate. During BIO 2026 in San Diego, Henny Zijlstra, Chief Commercial Officer at Ardena, sat down with BioPharma Boardroom to discuss how integrated CDMO strategies are shaping the future of early-phase pipelines. […]
Real-world examples of how our expertise has helped partners advance their programs.
Poor aqueous solubility remains a formidable barrier in drug development, with approximately 90% of new chemical entities facing significant challenges in achieving effective bioavailability. To overcome these limitations, pharmaceutical developers frequently employ solubility enhancement techniques, ranging from particle size reduction to solid-state modifications and advanced formulation-based strategies. At Ardena, our approach emphasizes salt screening, lipid-based […]
A shift to a four-arm, multi-dose Phase IIa protocol introduced new requirements for dosing accuracy, traceability, and patient usability. Learn how Ardena designed a modular secondary packaging solution that integrated existing blister configurations and enabled seamless execution of the updated clinical design.
Long-acting biologics present specific challenges for immunogenicity assessment, particularly when residual drug interferes with ADA detection. In this case study, Ardena outlines how a drug-tolerant ADA assay was established for a high-dose monoclonal antibody, enabling reliable detection in samples with high circulating drug levels. Discover how targeted optimisation of a PandA-based approach delivered a robust, […]
In-depth scientific papers from our experts on emerging methods and technologies.
Delumping is an established operation in pharmaceutical manufacturing, used to produce more homogeneous, free-flowing powders across drug substance and drug product processes. When agglomeration is left unaddressed, it can affect powder flow, charging, homogeneity, downstream processing, cycle time and yield. In this technical paper, Kim Geurts, Scientist PR&D and Manufacturing, Enabling Chemistry, explains how Ardena […]
Nanomedicines demand tight control over particle properties, reproducibility, and scalability, yet conventional batch methods often struggle to deliver all three. In this whitepaper, Ardena’s nanomedicines experts Mark van Eldijk and Andy Bänziger explore how flow manufacturing can enable more consistent nanoparticle production, simplify scale-up, and support robust development pathways from early-stage research through GMP manufacturing. […]
The ICH has released a draft consolidated guideline (ICH Q1) that unifies the previous Q1A–Q1F series into a single global standard. This revision simplifies stability requirements, integrates lifecycle management, and expands the scope to advanced therapies and drug-device combinations. This whitepaper provides a clear overview of the key changes — from predictive tools and modeling […]
Conversations with our scientists and partners on drug development science.
Coming soon — stay tuned.
